Chronic adrenergic stress and generation of myeloid-derived suppressor cells: Implications for cancer immunotherapy in dogs.
cytokines
immune cells
macrophage
norepinephrine
thermal stress
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
28
02
2023
received:
23
01
2023
accepted:
01
03
2023
medline:
18
5
2023
pubmed:
7
3
2023
entrez:
6
3
2023
Statut:
ppublish
Résumé
Recent studies have highlighted a key role played by the sympathetic nervous system (SNS) and adrenergic stress in mediating immune suppression associated with chronic inflammation in cancer and other diseases. The connection between chronic SNS activation, adrenergic stress and immune suppression is linked in part to the ability of catecholamines to stimulate the bone marrow release and differentiation of myeloid-derived suppressor cells (MDSC). Rodent model studies have revealed an important role for β-adrenergic receptor signalling in suppression of cancer immunity in mice subjected to chronic stresses, including thermal stress. Importantly, therapeutic blockade of beta-adrenergic responses by drugs such as propranolol can partially reverse the generation and differentiation of MDSC, and partly restore tumour immunity. Clinical trials in both humans and dogs with cancer have demonstrated that propranolol blockade can improve responses to radiation therapy, cancer vaccines and immune checkpoint inhibitors. Thus, the SNS stress response has become an important new target to relieve immune suppression in cancer and other chronic inflammatory conditions.
Substances chimiques
Propranolol
9Y8NXQ24VQ
Adrenergic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-165Subventions
Organisme : NIH HHS
Pays : United States
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2023 The Authors. Veterinary and Comparative Oncology published by John Wiley & Sons Ltd.
Références
Chen M, Singh AK, Repasky EA. Highlighting the potential for chronic stress to minimize therapeutic responses to radiotherapy through increased immunosuppression and radiation resistance. Cancers (Basel). 2020;12:3853-3870.
Bucsek MJ, Giridharan T, MacDonald CR, et al. An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia. 2018;34:135-143.
Manni M, Maestroni GJ. Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: involvement of beta-adrenoceptors and relevance in inflammatory diseases. Brain Behav Immun. 2008;22:80-88.
Mohammadpour H, MacDonald CR, McCarthy PL, et al. beta2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. Cell Rep. 2021;37:109883.
Mohammadpour H, Sarow JL, MacDonald CR, et al. Beta2-adrenergic receptor activation on donor cells ameliorates acute GvHD. JCI Insight. 2020;5:1-26.
Ortega E, Galvez I, Martin-Cordero L. Adrenergic regulation of macrophage-mediated innate/inflammatory responses in obesity and exercise in this condition: role of beta2 adrenergic receptors. Endocr Metab Immune Disord Drug Targets. 2019;19:1089-1099.
Qiao G, Chen M, Mohammadpour H, et al. Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment. Cancer Immunol Res. 2021;9:651-664.
Mohammadpour H, MacDonald CR, Qiao G, et al. Beta2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. J Clin Invest. 2019;129:5537-5552.
Mohammadpour H, O'Neil R, Qiu J, et al. Blockade of host beta2-adrenergic receptor enhances graft-versus-tumor effect through modulating APCs. J Immunol. 2018;200:2479-2488.
Barbieri A, Robinson N, Palma G, Maurea N, Desiderio V, Botti G. Can Beta-2-adrenergic pathway Be a new target to combat SARS-CoV-2 hyperinflammatory syndrome?-lessons learned from cancer. Front Immunol. 2020;11:588724.
Molinoff PB. Alpha- and beta-adrenergic receptor subtypes properties, distribution and regulation. Drugs. 1984;28(suppl 2):1-15.
Kyrou I, Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr Opin Pharmacol. 2009;9:787-793.
Tsigos C, Kyrou I, Kassi E, et al. Stress: Endocrine Physiology and Pathophysiology. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. MDText is publisher, online forum; 2000.
Hu P, Lu Y, Pan BX, Zhang WH. New insights into the pivotal role of the amygdala in inflammation-related depression and anxiety disorder. Int J Mol Sci. 2022;23:1-20.
Eng JW, Reed CB, Kokolus KM, et al. Housing temperature-induced stress drives therapeutic resistance in murine tumour models through beta2-adrenergic receptor activation. Nat Commun. 2015;6:6426.
Eng JW, Reed CB, Kokolus KM, et al. Housing temperature influences the pattern of heat shock protein induction in mice following mild whole body hyperthermia. Int J Hyperthermia. 2014;30:540-546.
Hylander BL, Eng JW, Repasky EA. The impact of housing temperature-induced chronic stress on preclinical mouse tumor models and therapeutic responses: an important role for the nervous system. Adv Exp Med Biol. 2017;1036:173-189.
Hylander BL, Gordon CJ, Repasky EA. Manipulation of ambient housing temperature to study the impact of chronic stress on immunity and cancer in mice. J Immunol. 2019;202:631-636.
Kokolus KM, Spangler HM, Povinelli BJ, Farren MR, Lee KP, Repasky EA. Stressful presentations: mild cold stress in laboratory mice influences phenotype of dendritic cells in naive and tumor-bearing mice. Front Immunol. 2014;5:23.
Leigh ND, Kokolus KM, O'Neill RE, et al. Housing temperature-induced stress is suppressing murine graft-versus-host disease through beta2-adrenergic receptor signaling. J Immunol. 2015;195:5045-5054.
Repasky EA, Evans SS, Dewhirst MW. Temperature matters! And why it should matter to tumor immunologists. Cancer Immunol Res. 2013;1:210-216.
Sen A, Capitano ML, Spernyak JA, et al. Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. Cancer Res. 2011;71:3872-3880.
Povinelli BJ, Kokolus KM, Eng JW, et al. Standard sub-thermoneutral caging temperature influences radiosensitivity of hematopoietic stem and progenitor cells. PLoS One. 2015;10:e0120078.
Messmer MN, Kokolus KM, Eng JW, et al. Mild cold-stress depresses immune responses: implications for cancer models involving laboratory mice. Bioessays. 2014;36:884-891.
Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15:335-349.
Repasky EA, Eng J, Hylander BL. Stress, metabolism and cancer: integrated pathways contributing to immune suppression. Cancer J. 2015;21:97-103.
Qiao G, Bucsek MJ, Winder NM, et al. Beta-adrenergic signaling blocks murine CD8(+) T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress. Cancer Immunol Immunother. 2019;68:11-22.
Qiao G, Chen M, Bucsek MJ, Repasky EA, Hylander BL. Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response. Front Immunol. 2018;9:164.
Zhou L, Li Y, Li X, et al. Propranolol attenuates surgical stress-induced elevation of the regulatory T cell response in patients undergoing radical mastectomy. J Immunol. 2016;196:3460-3469.
Jean Wrobel L, Bod L, Lengagne R, et al. Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. Oncotarget. 2016;7:77825-77837.
Barnes MA, Carson MJ, Nair MG. Non-traditional cytokines: how catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system. Cytokine. 2015;72:210-219.
Douglass SM, Fane ME, Sanseviero E, et al. Myeloid-derived suppressor cells are a major source of Wnt5A in the melanoma microenvironment and depend on Wnt5A for full suppressive activity. Cancer Res. 2021;81:658-670.
Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174.
Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208-220.
Gabrilovich DI. Myeloid-derived suppressor cells. Cancer. Immunol Res. 2017;5:3-8.
Medina E, Hartl D. Myeloid-derived suppressor cells in infection: a general overview. J Innate Immun. 2018;10:407-413.
Kwak T, Wang F, Deng H, et al. Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer. Cell Rep. 2020;33:108571.
Goulart MR, Hlavaty SI, Chang YM, et al. Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Sci Rep. 2019;9:3574.
Hutchison S, Sahay B, de Mello SC, et al. Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy. Vet Immunol Immunopathol. 2019;216:109912.
Jackson K, Milner RJ, Doty A, et al. Analysis of canine myeloid-derived suppressor cells (MDSCs) utilizing fluorescence-activated cell sorting, RNA protection mediums to yield quality RNA for single-cell RNA sequencing. Vet Immunol Immunopathol. 2021;231:110144.
Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med. 2011;17:281-292.
Dorhoi A, Du Plessis N. Monocytic myeloid-derived suppressor cells in chronic infections. Front Immunol. 2017;8:1895.
Kolahian S, Oz HH, Zhou B, et al. The emerging role of myeloid-derived suppressor cells in lung diseases. Eur Respir J. 2016;47:967-977.
Bruger AM, Vanhaver C, Bruderek K, et al. Protocol to assess the suppression of T-cell proliferation by human MDSC. Methods Enzymol. 2020;632:155-192.
Xiang X, Poliakov A, Liu C, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009;124:2621-2633.
Kumagai S, Togashi Y, Sakai C, et al. An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity. 2020;53:187-203.e8.
Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression-implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356-371.
Kamada T, Togashi Y, Tay C, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116:9999-10008.
Liu Y, Yu Y, Yang S, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother. 2009;58:687-697.
Chen M, Qiao G, Hylander BL, et al. Adrenergic stress constrains the development of anti-tumor immunity and abscopal responses following local radiation. Nat Commun. 2020;11:1821.
Hinkle L, Liu Y, Meng C, et al. The sympathetic nervous system modulates cancer vaccine activity through monocyte-derived cells. J Immunol. 2021;207:3131-3140.
Ashrafi S, Shapouri R, Mahdavi M. Immunological consequences of immunization with tumor lysate vaccine and propranolol as an adjuvant: a study on cytokine profiles in breast tumor microenvironment. Immunol Lett. 2017;181:63-70.
Ashrafi S, Shapouri R, Shirkhani A, Mahdavi M. Anti-tumor effects of propranolol: adjuvant activity on a transplanted murine breast cancer model. Biomed Pharmacother. 2018;104:45-51.
Daher C, Vimeux L, Stoeva R, et al. Blockade of beta-adrenergic receptors improves CD8(+) T-cell priming and cancer vaccine efficacy. Cancer Immunol Res. 2019;7:1849-1863.
Gandhi S, Pandey MR, Attwood K, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 2021;27:87-95.
Farrugia MK, Ma SJ, Mattson DM, Flaherty L, Repasky EA, Singh AK. Concurrent beta-blocker use is associated with improved outcome in esophageal cancer patients who undergo chemoradiation: a retrospective matched-pair analysis. Am J Clin Oncol. 2020;43:889-894.
Gandhi S, Pandey M, Ammannagari N, et al. Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors. Immunotherapy. 2020;12:141-149.
Kokolus KM, Zhang Y, Sivik JM, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Onco Targets Ther. 2018;7:e1405205.
MacDonald CR, Bucsek MJ, Qiao G, et al. Adrenergic receptor signaling regulates the response of tumors to ionizing radiation. Radiat Res. 2019;191:585-589.
Liao X, Chaudhary P, Qiu G, Che X, Fan L. The role of propranolol as a radiosensitizer in gastric cancer treatment. Drug Des Devel Ther. 2018;12:639-645.
Liao X, Che X, Zhao W, et al. Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat Oncol. 2010;5:98.
Duckett MM, Phung SK, Nguyen L, et al. The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells. Vet Comp Oncol. 2020;18:128-140.
Chaudhary KR, Yan SX, Heilbroner SP, et al. Effects of beta-adrenergic antagonists on chemoradiation therapy for locally advanced non-small cell lung cancer. J Clin Med. 2019;8:575-591.
Lee CT, Zhong L, Mace TA, Repasky EA. Elevation in body temperature to fever range enhances and prolongs subsequent responsiveness of macrophages to endotoxin challenge. PLoS One. 2012;7:e30077.
Khanna C, Lindblad-Toh K, Vail D, et al. The dog as a cancer model. Nat Biotechnol. 2006;24:1065-1066.
Magee K, Marsh IR, Turek MM, et al. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS One. 2021;16:e0255798.
Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000;18:781-792.
Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis. 2005;26:513-523.
Saba C, Paoloni M, Mazcko C, et al. A comparative oncology study of iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model. PLoS One. 2016;11:e0149194.
Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995;1:1165-1170.
MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:4249-4258.
Ampudia-Mesias E, Puerta-Martinez F, Bridges M, et al. CD200 immune-checkpoint peptide elicits an anti-glioma response through the DAP10 signaling pathway. Neurotherapeutics. 2021;18:1980-1994.
Hubbard ME, Arnold S, Bin Zahid A, et al. Naturally occurring canine glioma as a model for novel therapeutics. Cancer Invest. 2018;36:415-423.
Olin MR, Pluhar GE, Andersen BM, Shaver R, Waldron NN, Moertel CL. Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol. 2014;34:399-432.
Mucha J, Rybicka A, Dolka I, et al. Immunosuppression in dogs during mammary cancer development. Vet Pathol. 2016;53:1147-1153.
Goulart MR, Hlavaty SI, Chang Y-M, et al. Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Sci Rep. 2019;9:1-14.
Borgatti A, Dickerson EB, Lawrence J. Emerging therapeutic approaches for canine sarcomas: pushing the boundaries beyond the conventional. Vet Comp Oncol. 2020;18:9-24.
Ammons DT, Guth A, Rozental AJ, et al. Reprogramming the canine glioma microenvironment with tumor vaccination plus oral losartan and propranolol induces objective responses. Cancer Res Commun. 2022;2:1657-1667.